Product Catalog[{"id":"480","name":"Tivdak","price":1,"sku":"Tivdak (tisotumab vedotin-tftv)","brand":"Seattle Genetics, Genmab","position":1,"category":"Medicines\/Oncology"},{"id":"478","name":"Daurismo","price":1,"sku":"Daurismo (glasdegib)","brand":false,"position":2,"category":"Medicines\/Oncology"},{"id":"477","name":"Xospata","price":1,"sku":"Xospata (gilteritinib)","brand":"Astellas Pharma Inc.","position":3,"category":"Medicines\/Oncology"},{"id":"474","name":"Exkivity","price":1,"sku":"Exkivity (mobocertinib)","brand":"Takeda Pharma A\/S","position":4,"category":"Medicines\/Oncology"},{"id":"463","name":"Evaluation of Parsaclisib plus Bendamustine and Rituximab in patients with Newly Diagnosed Mantle Cell Lymphoma","price":1,"sku":"lymphoma-trial-2","brand":false,"position":5,"category":"Medicines\/Oncology"},{"id":"462","name":"Evaluation of Tafasitamab plus Rituximab and Lenalidomide in patients with Lymphoma that has stopped responding to treatment","price":1,"sku":"lymphoma-trial-3","brand":false,"position":6,"category":"Medicines\/Oncology"},{"id":"461","name":"Evaluation of Parsaclisib plus Rituximab or Obinutuzumab in patients with Lymphoma that has stopped responding to treatment","price":1,"sku":"lymphoma-trial-4","brand":false,"position":7,"category":"Medicines\/Oncology"},{"id":"460","name":"Evaluation of Tafasitamab plus Parsaclisib in patients with Non Hodgkin Lymphoma or Chronic Lymphocytic Leukemia","price":1,"sku":"lymphoma-leukemia-trial-1","brand":false,"position":8,"category":"Medicines\/Oncology"},{"id":"459","name":"Evaluation of Parsaclisib plus Ruxolitinib in patients with Myelofibrosis who have not responded to Ruxolitinib alone","price":1,"sku":"myelofibrosis-trial-1","brand":false,"position":9,"category":"Medicines\/Oncology"}]
